Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Inclusion Criteria:

* Histologically confirmed endometrial cancer, including 1 of the following cellular types:

  * Endometrioid endometrial adenocarcinoma
  * Clear cell carcinoma
  * Papillary serous adenocarcinoma
  * Adenosquamous cell carcinoma
  * Other adenocarcinoma variant
* No carcinosarcoma
* Meets 1 of the following criteria:

  * Grade 3 carcinoma with \> 50% myometrial invasion (stage IC or IIA) (all papillary serous or clear cell carcinoma will be considered grade 3)
  * Grade 2 or 3 carcinoma with any cervical stromal invasion (stage IIB)
  * Known extra-uterine disease confined to the pelvis (stage III or IVA)

    * Patients with stage III or IVA disease must have undergone computed tomography (CT) scan or positron emission tomography (PET)/CT scan of the abdomen and pelvis within the past 56 days
* Has undergone hysterectomy (i.e., total abdominal, vaginal, robotic-assisted, radical, or laparoscopic-assisted vaginal hysterectomy) and bilateral salpingo-oophorectomy within the past 56 days
* No positive common iliac or positive para-aortic nodal disease (defined as lymph nodes ? 2 cm in any dimension on CT scan or biopsy) or positive peritoneal cytology
* No evidence of metastatic extrauterine disease, gross or residual disease (not including pelvic nodal disease), or distant metastases
* Zubrod performance status 0-1
* Absolute neutrophil count (ANC) ? 1,500/mm\^3 (without growth factor support)
* Platelet count ? 100,000/mm\^3
* Hemoglobin ? 10 g/dL (transfusion allowed)
* Total bilirubin ? 1.5 times upper limit of normal (ULN)
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2 times ULN
* Serum creatinine ? 1.5 mg/dL
* Urine protein:creatinine ratio ? 0.5 OR urine protein \< 1,000 mg on 24-hour urine collection
* International normalized ratio (INR) \< 1.5 (for patients treated with warfarin within the past 14 days)
* Not nursing
* No neuropathy ? Common Terminology Criteria for Adverse Events (CTCAE) grade 1
* No ototoxicity \> CTCAE grade 2
* No serious, active comorbidity, including any of the following:

  * Unstable angina and/or New York Heart Association (NYHA) class II-IV congestive heart failure requiring hospitalization within the past 12 months
  * Transmural myocardial infarction within the past 12 months
  * Acute bacterial or fungal infection requiring IV antibiotics
  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy
  * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
  * Acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control (CDC) definition (human immunodeficiency virus \[HIV\] testing is not required)
  * Active gastrointestinal (GI) ulcers, GI bleeding, inflammatory bowel disease, or GI obstruction
  * Inadequately controlled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg and/or diastolic BP \> 90 mm Hg on antihypertensive medications
  * Significant vascular disease, including aortic aneurysm, aortic dissection, or arteriovenous malformation within the past 12 months
  * Serious cardiac arrhythmia on medication (well-controlled atrial fibrillation on medication allowed)
  * Serious non-healing wound, ulcer, or bone fracture
* No history of hypertensive crisis or hypertensive encephalopathy
* No stroke/cerebrovascular event within the past 12 months
* No arterial thromboembolic events, including transient ischemic attack or clinically symptomatic peripheral artery disease within the past 12 months
* No abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6 months
* No other invasive malignancies within the past 3 years other than nonmelanomatous skin cancer
* No significant trauma within the past 28 days
* No mental status changes or bladder problems that would preclude the ability to comply with bladder-filling instructions
* No mental or psychiatric illness that would preclude giving informed consent
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
* No prior allergic reaction to bevacizumab, cisplatin, carboplatin, or paclitaxel
* No concurrent erythropoietin, St. John's wort, therapeutic anticoagulants, aminoglycoside antibiotics, or amifostine
* No prior organ transplantation
* No prior external-beam radiotherapy to the pelvis resulting in overlapping of radiotherapy fields
* No prior systemic chemotherapy for uterine cancer

  * Prior chemotherapy for a different cancer is allowed
* No prior therapy with anti-vascular endothelial growth factor (VEGF) compounds
* More than 28 days since prior major surgical procedure requiring open biopsy incision
* No concurrent surgery (except for vascular access device placement or procedures that do not require significant incision)
* No concurrent warfarin at doses \> 1 mg/day

  * Concurrent prophylactic low molecular weight heparin allowed